Concerns Mount Over Retatrutide Usage Following Fatal Incidents

In July, a 41-year-old woman suffered cardiac arrest after taking retatrutide, a drug from what a healthcare worker described as an “unreliable source.” Then, in September, another report emerged of a 49-year-old individual who also died from cardiac arrest after experiencing severe dehydration and malnutrition, having obtained the drug online based on a nurse’s recommendation. Both incidents were reported to the Food and Drug Administration (FDA), and CBS News managed to access the records through a public records request.

It’s important to note that these adverse event reports can’t definitively determine the cause of death. Yet, regulatory authorities are supposed to investigate such incidents, and these cases indicate a product that should never have been accessible to the public.

Retatrutide is an experimental weight-loss drug developed by Eli Lilly that remains in clinical trials. The early results were impressive enough to generate interest long before any approval had been granted. As of now, no country has authorized it for human use. The FDA has stated that the drug “has not been found safe and effective for any condition,” and federal regulations prohibit pharmacies from compounding it.

I happen to take a GLP-1 myself, so I can appreciate the demand for such medications. According to Gallup, around 11% of American adults are now using these drugs for weight loss—a significant increase compared to just four percent in 2024. I’ve personally witnessed the positive impacts they can have on health, but I’ve also seen the hefty bills that come with them. Brand-name prescriptions can be quite expensive, and insurance coverage often varies. Interestingly, Gallup found that over half of those who turned to cheaper compounded versions did so primarily for financial reasons or due to issues with their insurance. Given that context, the prospect of a six-month supply of retatrutide for just $150 can seem pretty appealing. However, safety should always outweigh cost considerations. My prescription is filled through a legitimate pharmacy, so I can trust its contents. But someone ordering vials online? They have no idea what they might be getting.

A lot of this inexpensive supply seems to originate in China. Investigative reports have traced factories there that market retatrutide to American consumers on social media, offering shipping via mail and even accepting Bitcoin as payment. Just last month, in the Washington Examiner, Jennifer Nunez highlighted how the drug is appearing on TikTok and in medical spas, with reports of teenagers accessing it. The vials typically bear the label “research use only,” and they often include dosing instructions, which raises questions about who the sellers expect to use them.

Regulatory bodies have started to notice this trend. The FDA has warned companies selling products falsely labeled “for research purposes” that are being marketed for human consumption. Consumers have no means to verify the dose or the manufacturing process behind these products.

We’ve seen similar situations unfold before. In 2016 and 2017, high-purity fentanyl sourced from China accounted for 97% of the fentanyl the Drug Enforcement Administration (DEA) seized in shipments intended for the U.S. Eventually, Beijing banned fentanyl itself, yet chemical suppliers simply adapted by selling precursors to cartels in Mexico. Even today, U.S. intelligence identifies China as a leading supplier of these substances. By the time genuine pressure from Washington prompted real cooperation, synthetic opioids were already claiming nearly 78,000 lives annually in America.

While retatrutide poses different risks, its supply chain shares similarities. So does Beijing’s approach to permitting profitable exports until the U.S. escalates its concerns. We shouldn’t wait for a rising death toll before taking action this time.

The rules themselves seem clear on paper, but the enforcement has not kept pace with the growing problem. Companies that receive warning letters often find ways to reestablish themselves under new names. An overseas vendor shipping small packages knows that most shipments will likely pass through customs undetected. Add to that the influence of social media, where an influencer can direct thousands of young followers to an online store within a day.

There’s a clear path for Washington to intervene. The FDA along with Customs and Border Protection should prioritize the detention of retatrutide shipments, starting with those from China. Furthermore, the administration should push Beijing to regulate peptide exports in a similar way to how it has sought to manage fentanyl precursors. Warning letters need to hold significant weight. If a company disregards one, the FDA and the Justice Department should act to implement seizures and injunctions. Serious repeat offenders should face legal action under the Federal Food, Drug, and Cosmetic Act. The presence of a “research use only” label alongside dosing instructions suggests intent, and that should be treated accordingly by prosecutors. Collaboration between the FDA and social media platforms is essential to eliminate accounts targeting minors, as is cooperation with state licensing boards to hold accountable nurses and other professionals who guide patients toward dangerous products.

Moreover, public transparency is crucial: the agencies should provide statistics on how many shipments have been intercepted, how many warning letters have resulted in enforcement actions, and whether illegal sales are decreasing. A significant amount of this information is likely already at their disposal.

There’s no need for Congress to create additional legislation. The FDA signaled its stance on retatrutide months ago, and the two reported fatalities indicate that this stance isn’t being upheld. We need enforcement to catch up with the black market before anymore tragic incidents occur.